Kerr Drug rolls out BloodSTOP
MOUNTAIN VIEW, Calif. Kerr Drug last week announced the introduction of a new bleeding control solution to its market with the introduction of BloodSTOP hemostatic gauze, manufactured by LifeScience PLUS.
“When I first saw BloodSTOP and the way it works, I was immediately interested,” stated Scott Porter, category manager – healthCare, Kerr Drug. “After sampling the product I was sold. BloodSTOP offers an exciting solution to a sleepy category. Kerr Drug is always looking for niche items that provide real and innovative solutions for our customers. I believe we hit a homerun here.”
Resembling a traditional bandage, BloodSTOP acts in less than a minute, reducing clotting times by as much as 75%. When applied to a wound, BloodSTOP quickly absorbs blood and other body fluids, transforms into a gel to seal the wound with a protective transparent layer, actively aids in blood coagulation, and creates an environment for wound healing. It is water soluble for easy removal without discomfort or disruption to the wound surface.
CHPA elects new board members
WASHINGTON The Consumer Healthcare Products Association on Nov. 17 elected new board members and executive committee vice chairs, the association announced last week in its newsletter.
CHPA’s new board members include:
- William Hemelt, president and CEO, Matrixx Initiatives;
- Colleen Jay, VP North America personal health, global digestive wellness, Procter & Gamble;
- Matthew Mannelly, president and CEO, Prestige Brands;
- James Medford, president and CEO, Aaron Industries;
- Jeffrey Rowan, president and CEO, Fleet Laboratories; and
- Paul Sturman, president and GM, Pfizer Consumer Healthcare.
CHPA elected Charles Hough, OTC Business Unit, region head – North America, Novartis Consumer Health, Peter Luther, president, McNeil Consumer Healthcare; and Roger Scarlett-Smith, president, North America, Consumer Healthcare, GlaxoSmithKline as executive committee vice chairs.
In addition, CHPA’s board of directors elected four active member companies, including: Boiron, Essential Home OTCs, Heatmax and Honey Don’t Cough.
NARB denies Novartis’ appeal for Excedrin ad claims
NEW YORK The National Advertising Review Board last week denied an appeal made by Novartis Consumer Health around the advertising claim that Extra Strength Excedrin relieves pain after 15 minutes.
Following a challenge made by Wyeth Consumer Healthcare, the National Advertising Division of the Council of Better Business Bureaus had advised Novartis to discontinue the 15-minute claim.
The challenged television advertisement showed a woman suffering from a headache sitting at a table at an outdoor cafe. A digital clock rapidly advances below her. When the clock indicates 10 minutes had passed, a voiceover asks: “What’s the only gel tab with a triple-ingredient formula to start relieving your headache in just 15 minutes?”
At the 15-minute mark, the woman’s facial expression dramatically changes and she gets up, smiling, to greet someone. The voiceover answers the question by stating “Extra Strength Excedrin. Go.”
Novartis provided a proprietary clinical study that tested Extra Strength Excedrin to determine its efficacy in relieving pain intensity for episodic tension-type headaches, and argued that the clinical trial was sufficient to support an “onset of action” claim that Extra Strength Excedrin started to work on a pharmacological basis after 15 minutes.
The appeal panel agreed with NAD’s initial finding that the proffered substantiation did not provide support for the reasonably conveyed message that typical consumers can reasonably expect a reduction in headache pain within 15 minutes of taking Extra Strength Excedrin.
Novartis agreed to follow NARB’s recommendation.